Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy showed no clear difference in overall severe adverse events (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
- Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes onlyRR 1.11 [0.95, 1.3]2 studies · 834 participantsModerate